Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS

Autologous dendritic cells generated using GM-CSF, interferon alpha, and LPS represent a type of cell therapy primarily developed for cancer immunotherapy. These cells are derived from a patient's own monocytes or peripheral blood mononuclear cells (PBMCs) through an ex vivo differentiation and maturation process. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon alpha (IFN-alpha) are used to induce the differentiation of monocytes into immature dendritic cells (DCs) and promote their maturation. Lipopolysaccharide (LPS), a potent innate immune stimulator, is then typically used as a maturation stimulus to further activate these DCs. The resulting mature dendritic cells are highly effective antigen-presenting cells (APCs) capable of processing and presenting tumor-associated antigens to T lymphocytes, thereby initiating and enhancing specific anti-tumor immune responses. This approach aims to 'educate' the patient's immune system to recognize and attack cancer cells.